First-line latanoprost therapy in ocular hypertension or open-angle glaucoma patients: a 3-month efficacy analysis stratified by initial intraocular pressure

Table 3 Summary of adverse events, safety population (N = 590)*

	Baseline Intraocular Pressure
Subjects with:	20 to <24 mmHg N = 262	≥ 24 mmHg N = 328
≥ 1 adverse event^†	111 (42.4) [159]	126 (38.4) [180]
≥ 1 treatment-related adverse event^†	83 (31.7) [109]	99 (30.2) [126]
≥ 1 serious adverse event	5 (1.9) [5]	4 (1.2) [5]
≥ 1 adverse event leading to treatment discontinuation	5 (1.9) [7]	8 (2.4) [13]

*n (%) of subjects [number of events].
^†Patient-reported use of a bottle of latanoprost beyond its expiration date, i.e., for >28 days after opening, was reported by 54 subjects in the 20 to <24 mmHg group and by 65 subjects in the ≥ 24 mmHg group. These were counted as adverse events and as treatment-related adverse events. No other ocular or systemic adverse event was associated with extended use in any subject.

ISSN: 1471-2415